Subtype
Oropharyngeal Neoplasm
CI-CAN-00003505Explore in graph →
Non-malignant147 active trials2 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003505Explore in graph →
Clinical trials
487 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03799445 | Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT04162873 | Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | terminated | Phase 2 | 13 | University of UtahOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT03618134 | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner | terminated | Phase 1 / Phase 2 | 19 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02917629 | ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03258008 | Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 16, 2022 | clinicaltrials |
| NCT04015336 | E7 TCR Cell Induction Immunotherapy for Stage II and Stage III HPV-Associated Oropharyngeal Cancer | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2022 | clinicaltrials |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT02706691 | BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer | terminated | Phase 2 | 1 | University of ChicagoOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01525927 | Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity | terminated | Phase 2 | 2 | Northwell HealthOTHER | 1 | Dec 19, 2017 | clinicaltrials |
| NCT02225496 | Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2017 | clinicaltrials |
| NCT02068157 | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Oct 11, 2017 | clinicaltrials |
| NCT02196168 | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | May 3, 2017 | clinicaltrials |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | terminated | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 2 | Apr 14, 2017 | clinicaltrials |
| NCT01682031 | Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 2 | Aug 22, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 30, 2026source: clinicaltrials